How To Make Polyarticular Juvenile Idiopathic Arthritis Drugs Market

How To Make Polyarticular Juvenile Idiopathic Arthritis Drugs Market

Polyarticular juvenile idiopathic arthritis drugs market is segmented based on Drug Type, Distribution Channel, and by region

2021-03-19

Development of Biosimilars

The treatment of Polyarticular Juvenile Idiopathic Arthritis (PJIA) involves the use of a wide range of medications. The market is witnessing a large number of drug launches with increasing market potential. Adalimumab is the first approved antibody that blocks tumor necrosis factor (TNF), a small inflammatory protein that is associated with the occurrence of JIA. Humira is the patented Adalimumab drug with AbbVie and has evolved as the largest sold drug. The rise of PJIA cases and increasing awareness of treatment are motivating drug manufacturers toward the launch of biosimilars. However, biosimilars are restricted for patient availability till July 2023, following the patent agreement held with AbbVie. In November 2019, The United States Food and Drug Administration (FDA) approved Pfizer’s Abrilada (adalimumab-AFB), a biosimilar to Humira for the treatment of juvenile idiopathic arthritis (JIA) in patients aged 4 years and older. The company is planning to market biosimilar to U.S. patients by 2023. FDA also approved Hulio (adalimumab-fkjp) in July 2020. Developed by Mylan and Fujifilm Kyowa Kirin Biologics, the formulation is considered the sixth adalimumab biosimilar for adalimumab. The approval is based on clinical studies in use against juvenile idiopathic arthritis, psoriatic arthritis, rheumatoid arthritis, and various other conditions. Also, the growing research activities about the efficacy and safety of biosimilars in children are likely to promote the development of JIA biosimilars, thereby supporting market growth. Biosimilars are finding use as first-line and subsequent-line biologic therapy in children with JIA.

Covid-19 Impact Analysis

As the coronavirus disease 2019 (COVID-19) pandemic spreads, it will continue to affect the pharmaceutical industry. Polyarticular Juvenile Idiopathic Arthritis treatment is no exception, and the effect on its drug market will be multifaceted. Inaccessibility of healthcare providers (HCPs) and other medical decision-makers led to a little decline in PJIA treatment procedures. During the spread of the novel coronavirus and social restrictions imposed thereof, patients diagnosed with early stage of PJIA have delayed treatment procedures. This will slow down medication uptake across the world. Also, manufacturers that are preparing to launch new drugs during the lockdown period or the next may decide to postpone marketing or do a soft launch, which would entail supplying the product. This could affect the global PJIA drugs market during the COVID-19 period. Also, the market has been affected from the supply side owing to disruptions in the production of drugs. Freight challenges and trade restrictions led to an uneven supply of APIs, particularly from China. China and India are accounting for nearly 80% of the API demand in the U.S. Thus, these supply chain disruptions are likely to affect pharmaceutical manufacturing in many countries such as the U.S. and Europe. The annual growth of the global PJIA drugs market is likely to be recorded as 6.46% in 2020, down from that of 7.16% in 2019. However, the lowering number of new cases and ease of lockdown restrictions are leading to market recovery at a faster pace, particularly in the Asia Pacific region. 

Methotrexate

The Methotrexate segment for polyarticular juvenile idiopathic arthritis drugs market is likely to reach USD XX million in 2027, from its recorded value of USD XX million in 2019, growing at a CAGR of XX% during the forecast period. MTX is a conventional disease-modifying antirheumatic drug (DMARD) that fights the inflammation that can destroy joint cartilage and affect other organs. Methotrexate is widely considered one of the safest and most effective drugs for children with arthritis.  Methotrexate is used as a disease-modifying treatment for some autoimmune diseases, such as rheumatoid arthritis, juvenile dermatomyositis, psoriasis, psoriatic arthritis, lupus, sarcoidosis, Crohn's disease, eczema, and many forms of vasculitis. Methotrexate (Rheumatrex, Trexall) has an unknown mechanism of action in the treatment of inflammatory reactions. It ameliorates symptoms of inflammation (eg, pain, swelling, stiffness). The pediatric dosage is 10-25 mg/m2/wk PO/IM/SC as a single dose or divided into 2 doses weekly; many pediatric rheumatologists increase the dose (not to exceed 30 mg/m2, approximately equivalent to 1 mg/kg); administer with folic acid 1-2 mg PO QD or folinic acid 2.5-5 mg PO qwk. Methotrexate can be given orally, through pills or liquid, or by injection.

About Us:

DataM Intelligence was incorporated in the early weeks of 2017 as a Market Research and Consulting firm with just two people on board. Within less than a year, we have secured more than 100 unique customers from established organizations all over the world.

For more information:

Sai Kiran

Sales Manager at DataM Intelligence

Email: [email protected]

Tel: +1 877 441 4866

Website: www.datamintelligence.com

 

Found it interesting?

Sai Kiran
Sales Manager at DataM Intelligence
Email: [email protected]
Tel: +1 877 441 4866

We have 5000+ marketing reports and serve across 130+ countries

Tags:

#Polyarticular Juvenile Idiopathic Arthritis Drugs Market, #Polyarticular Juvenile Idiopathic Arthritis Drugs Market, #Polyarticular Juvenile Idiopathic Arthritis Drugs Market size, #Polyarticular Juvenile Idiopathic Arthritis Drugs Market share, #Polyarticular Juvenile Idiopathic Arthritis Drugs Market trends, #Polyarticular Juvenile Idiopathic Arthritis Drugs Market value, #Polyarticular Juvenile Idiopathic Arthritis Drugs Market growth, #Polyarticular Juvenile Idiopathic Arthritis Drugs Market demand, #Polyarticular Juvenile Idiopathic Arthritis Drugs Market industry forecast, #Polyarticular Juvenile Idiopathic Arthritis Drugs Market outlook, #Polyarticular Juvenile Idiopathic Arthritis Drugs Market analysis, #Polyarticular Juvenile Idiopathic Arthritis Drugs Market applications, #Polyarticular Juvenile Idiopathic Arthritis Drugs Market companies, #datamintelligence